Hyperscale Data (GPUS) shares rallied after the company said Monday that preliminary Q1 revenue exceeded $25 million.
Shares soared over 400% as intraday trading volume grew to over 253 million from a daily average of about 90,000.
Immutep (IMMP) said Monday that a phase 2b trial evaluating eftilagimod alfa in combination with Merck's (MRK) Keytruda as first line therapy in head and neck cancer patients produced an "excellent" median overall survival result of 17.6 months.
Shares soared 38% as intraday trading volume surged to over 5.51 million from a daily average of roughly 72,000.
BioCryst Pharmaceuticals (BCRX) shares jumped 15% following better-than-expected Q1 results.
Trading volume was more than 16 million, against a daily average of about 3.69 million.
Price: 7.15, Change: +5.78, Percent Change: +421.90
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。